INS and diabetes mellitus: The Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial showed exactly the same number of cancer cases with glargine treatment vs. standard care without insulin treatment over 6 years in subjects with prediabetes or early diabetes [13].